Background: The assessment of the risk of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolemia (HeFH) is determined by conventional risk factors. However, factors modifying CVD, or risk modifiers, beyond conventional risk factors may inform their CVD risk assessment and the subsequent use of new therapies. This work identifies and characterises patients within a lipid clinic cohort with regards to conventional CVD risk factors and risk modifiers with a focus on those with HeFH. Methods: A study of consecutive adult patients attending our specialist lipid clinic was performed over a six-month period. The patient data recorded included demographics, clinical characteristics, risk factors and risk modifiers, biochemical profiles and genetic testing results. Risk modifiers were identified based on ESC/EAS guidance, and those with HeFH were compared to those without. Results: A total of 370 patients were included. Of these, 98 HeFH patients were identified (26%). Then, 52% of HeFH patients were stratified into the very-high risk category due to the presence of CVD risk factors. Risk modifiers were present in 73%. These included a family history of premature CVD (56%), obesity (28%), a sedentary lifestyle (13%) and a major psychiatric disorder (12%). Compared to the rest of the cohort, those with HeFH were less likely to have hypertension and more likely to have a family history of premature CVD. Conclusions: Half of patients with HeFH are categorised as having very high CV risk. Consideration of risk modifiers, particularly a family history of premature CV disease, increases this very-high-risk category further. This may have implications for the clinical application and access to novel treatments.
Background: Hyperlipidaemia is common and most patients can be managed with established oral therapies and lifestyle modifications. However, patients with complex high-risk lipid disorders require specialist input and access to novel therapies to achieve treatment targets. While new agents are progressing through late phase trials, the eligibility criteria of these studies may limit their applicability to real-world settings. Aim: Assessing the generalisability of novel lipid-lowering therapy (LLT) trials by mapping their eligibility criteria to a cohort of patients attending a specialist lipid clinic. Methods: An ethically approved study was conducted at a specialist clinic in St James’s Hospital, Dublin over 6 months, enrolling 370 patients. Demographics, clinical characteristics, lipid profiles, genetic testing results and LLT use were collected. A structured search of clinicaltrials.gov and euclinicaltrials.eu identified phase 3 pharmacological trials registered since 2018. Patient data were then mapped against trial eligibility criteria to estimate the proportion of clinic patients that would have been eligible for each study. Results: In total, 38 trials were identified, including 15 different novel LLTs. It was found that the percentage of the cohort (n = 370) that would have been eligible for these LLT trials ranged from 0% to 62.4%, with an average eligibility of 19% across the 38 trials. Further analysis of specific patient subgroups and corresponding trial categories was performed. Conclusions: The included novel LLTs trials are reasonably applicable to a specialist lipid clinic cohort, suggesting generalisability to a wider group of real-world patients seen in clinics. This study can help guide future trial design by aligning eligibility criteria more closely with real-world patient populations, ensuring safe and effective clinical practice.